Is a synthetic form of erythropoietin, a hormone naturally produced by the kidneys that stimulates the production of red blood cells.
Treatment of anemia associated with chronic kidney disease (CKD) in adults and children.
Treatment of anemia in patients with cancer who are receiving chemotherapy.
Treatment of anemia in patients undergoing predialysis and dialysis.
Treatment of anemia in patients with myelodysplastic syndromes (MDS) who are not candidates for bone marrow transplantation.
Darbitop 40mcg Inj (Darbepoetin Alfa) acts by binding to erythropoietin receptors on red blood cell precursors in the bone marrow, stimulating their proliferation and differentiation, resulting in increased red blood cell production and a rise in hemoglobin levels.
Darbepoetin alfa should be stored refrigerated between 2°C and 8°C (36°F and 46°F). Protect from light.
The dosage of darbepoetin alfa is determined by the patient's individual needs and response to treatment.
It is typically administered intravenously or subcutaneously.
Dosage and frequency of administration should be adjusted based on hemoglobin levels and other factors.
It is crucial to follow the healthcare professional's instructions precisely for optimal therapeutic outcomes.
Serious side effects can occur, including high blood pressure, blood clots, stroke, heart attack, and pure red cell aplasia (PRCA) - a rare condition where the bone marrow stops producing red blood cells.
Common side effects include headache, fatigue, diarrhea, nausea, vomiting, and muscle pain.
Alcohol consumption can potentially interact with darbepoetin alfa, increasing the risk of side effects. Consult with your doctor before consuming alcohol.
Darbepoetin alfa may cause dizziness or fatigue. Avoid driving or operating machinery until you know how this medication affects you.
The safety of darbepoetin alfa during pregnancy and breastfeeding is not fully established. Discuss potential risks and benefits with your healthcare provider before using this medication.
Darbepoetin alfa is approved for use in children with chronic kidney disease, and the dosage is adjusted based on the child's weight.
Darbepoetin alfa is used to treat anemia associated with kidney disease. It is crucial to closely monitor kidney function during treatment.
Darbepoetin alfa is metabolized by the liver. Liver function should be monitored during treatment.
The United States Food and Drug Administration (FDA)
The European Medicines Agency (EMA)
The manufacturer's prescribing information
